713 related articles for article (PubMed ID: 12349893)
1. Extended-duration low-molecular-weight heparin prophylaxis following total joint arthroplasty.
Whang PG; Lieberman JR
Am J Orthop (Belle Mead NJ); 2002 Sep; 31(9 Suppl):31-6. PubMed ID: 12349893
[TBL] [Abstract][Full Text] [Related]
2. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
3. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
4. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
Colwell C; Mouret P
Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
[TBL] [Abstract][Full Text] [Related]
5. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
Bell GK; Goldhaber SZ
Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
[TBL] [Abstract][Full Text] [Related]
7. Deep vein thrombosis prophylaxis: a comprehensive approach for total hip and total knee arthroplasty patient populations.
Miric A; Lombardi P; Sculco TP
Am J Orthop (Belle Mead NJ); 2000 Apr; 29(4):269-74. PubMed ID: 10784014
[TBL] [Abstract][Full Text] [Related]
8. A prospective observational study on the effectiveness and safety of bemiparin, first dose administered 6 h after knee or hip replacement surgery.
Abad JI; Gómez-Outes A; Martínez-González J; Rocha E;
Arch Orthop Trauma Surg; 2007 Oct; 127(8):665-70. PubMed ID: 17089172
[TBL] [Abstract][Full Text] [Related]
9. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J;
Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738
[TBL] [Abstract][Full Text] [Related]
10. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
11. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.
Prescrire Int; 2005 Aug; 14(78):127-32. PubMed ID: 16106594
[TBL] [Abstract][Full Text] [Related]
12. [Thrombosis prophylaxis in orthopaedic surgery: considerations and uncertainties].
Ettema HB; Hoppener MR; Büller HR; Henny ChP; Verheyen CC
Ned Tijdschr Geneeskd; 2003 Sep; 147(38):1842-7. PubMed ID: 14533495
[TBL] [Abstract][Full Text] [Related]
13. Venous thromboembolic disease management patterns in total hip arthroplasty and total knee arthroplasty patients: a survey of the AAHKS membership.
Mesko JW; Brand RA; Iorio R; Gradisar I; Heekin R; Leighton R; Thornberry R
J Arthroplasty; 2001 Sep; 16(6):679-88. PubMed ID: 11547365
[TBL] [Abstract][Full Text] [Related]
14. Venous thromboembolism prophylaxis after hospital discharge: transition to preventive care.
Kaatz S; Spyropoulos AC
Hosp Pract (1995); 2011 Aug; 39(3):7-15. PubMed ID: 21881387
[TBL] [Abstract][Full Text] [Related]
15. Current recommendations for extended out-of-hospital thromboprophylaxis following total hip arthroplasty.
Krotenberg R
Am J Orthop (Belle Mead NJ); 2004 Apr; 33(4):180-4. PubMed ID: 15132325
[TBL] [Abstract][Full Text] [Related]
16. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
Huo MH; Muntz J
Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
[TBL] [Abstract][Full Text] [Related]
17. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Sarasin FP; Bounameaux H
Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
[TBL] [Abstract][Full Text] [Related]
18. DVT prophylaxis: better living through chemistry: affirms.
Pellegrini VD
Orthopedics; 2010 Sep; 33(9):642. PubMed ID: 20839678
[TBL] [Abstract][Full Text] [Related]
19. The role of low molecular weight heparin in total knee arthroplasty.
Iobst CA; Friedman RJ
Am J Knee Surg; 1999; 12(1):55-60. PubMed ID: 10050695
[TBL] [Abstract][Full Text] [Related]
20. [Heparin-induced thrombocytopenia after elective hip joint replacement with postoperative prevention of thromboembolism with low-molecular-weight heparin].
Marx A; Huhle G; Hoffmann U; Wang LC; Schüle B; Jani L; Harenberg J
Z Orthop Ihre Grenzgeb; 1999; 137(6):536-9. PubMed ID: 10666863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
